Partners

Developing Strategic Partnerships

ReadyCell counts on a wide range of strategic partners with which the company has developed strong and long-lasting strategic partnerships. This consists in collaboration, joint initiatives, common projects and more.

ADMEcell develops, manufactures and distributes Ready-to-Use products for in vitro therapeutic modeling and re-profiling. ADMECell provides products whose technology is relevant in the evolving and complex environment of ADME/Toxicology. Their products help you focus your resources on discovery and development, increasing your chances of success.
SOLVO is a codeveloper of PreadyPort™ kits. SOLVO develops transporter assays, based on the latest results in transporter science, the needs of the pharmaceutical industry and the guidelines for drug drug interaction studies by the FDA and EMA. With 17 years of experience and 500 customers in 40 countries, SOLVO Biotechnology is the leading provider of transporter services and products. Leveraging our expertise in efflux and uptake transporters, SOLVO generates quality reports for submission to FDA/EMA. From small molecules to protein therapeutics, SOLVO can test all your transporter needs.

NEXEL, Co., Ltd. is a bio-company that was incorporated in 2012 with proprietary stem cell technologies and cutting-edge techniques. They manufacture “more accurate, faster and easier” products from stem cells to develop more efficient tools for new drug discovery and incurable diseases. Additionally, they have discovered candidate proteins effective for liver fibrosis and cirrhosis. Their philosophy is to make a better place by supporting innovative research around the globe by providing a high quality of stem cell-derived cell products.

Genomembrane is a Japanase biotech company that has the aim to provie transporter- related products and services for the development and design of novel drugs for clinical application. Genomembrane also provides research tools and collaborates for the pharmaceutical evaluation of drug candidates in order to lessen cost and help advance the success rate of candidate drug, and speed up new drug development.

Leitat is a private technical institute with more than 110 years of experience in industrial innovation processes. It transforms technological and scientific results into economic and competitive value for its clients and collaborating entities. Over 1500 customers benefit from its talent, creativity and strong commitment. It brings knowledge and innovation to its customers through applied research and technical testing in the fields of chemistry, energy, environment, materials, engineering and life sciences. It relies upon its 240 highly skilled team members who deliver flexible solutions to face any industrial challenge.

IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer)is a centre for research of excellence that tackles high-prevalence, high-morbidity and high-mortality diseases. Founded in 1996, it is a public consortium whose members are the Catalan Government, the Hospital Clínic of Barcelona, the University of Barcelona’s School of Medicine and the CSIC Biomedical Research Institute in Barcelona.

ACCIÓ is the public agency for the competitiveness of the Catalan government. Its objective is to boost the competitiveness and growth of the Catalan businesses through the promotion of innovation, business internationalization and the attraction of investments. The agency accompanies and advises foreign companies during all phases of their projects, when looking for partners, the most competitive suppliers or the technology they need to establish in Catalonia. Currently, ACCIÓ accounts with a network of 40 foreign  offices worldwide and seven branches throughout Catalonia. It collaborates with local and international business entities to add synergies and ensure that the Catalan company has a broader range of tools to grow in competitiveness.

The Netherlands Cancer Institute was established on October 10, 1913. The founders wanted to create a cancer institute ‘where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied’. Nowadays, The Institute accommodates approximately 650 scientists and scientific support personnel. The Antoni van Leeuwenhoek Hospital has 185 medical specialists, 180 beds, an out-patients clinic with around 106,000 visits, 12 operating theaters and 11 irradiation units for radiotherapy.